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Cystic fibrosis (CF) disease provokes the accumulation of thick and viscous sputum in the
lungs, favoring the development of chronic and polymicrobial infections. Pseudomonas
aeruginosa is the main bacterium responsible for these chronic infections, and much of
the difficulty involved in eradicating it is due to biofilm formation. However, this could
be mitigated using adjuvant compounds that help or potentiate the antibiotic action.
Therefore, the main goal of this study was to search for substances that function
as adjuvants and also as biofilm-controlling compounds, preventing or dismantling
P. aeruginosa biofilms formed in an in vitro CF airway environment. Dual combinations
of compounds with subinhibitory (1 and 2 mg/L) and inhibitory concentrations (4
mg/L) of ciprofloxacin were tested to inhibit the bacterial growth and biofilm formation
(prophylactic approach) and to eradicate 24-h-old P. aeruginosa populations, including
planktonic cells and biofilms (treatment approach). Our results revealed that aspartic
acid (Asp) and succinic acid (Suc) restored ciprofloxacin action against P. aeruginosa.
Suc combined with 2 mg/L of ciprofloxacin (Suc-Cip) was able to eradicate bacteria,
and Asp combined with 4 mg/L of ciprofloxacin (Asp–Cip) seemed to eradicate the
whole 24-h-old populations, including planktonic cells and biofilms. Based on biomass
depletion data, we noted that Asp induced cell death and Suc seemed somehow to
block or reduce the expression of ciprofloxacin resistance. As far as we know, this
kind of action had not been reported up till now. The presence of Staphylococcus
aureus and Burkholderia cenocepacia did not affect the efficacy of the Asp–Cip and
Suc–Cip therapies against P. aeruginosa and, also important, P. aeruginosa depletion
from polymicrobial communities did not create a window of opportunity for these species
to thrive. Rather the contrary, Asp and Suc also improved ciprofloxacin action against
B. cenocepacia. Further studies on the cytotoxicity using lung epithelial cells indicated
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toxicity of Suc–Cip caused by the Suc. In conclusion, we provided evidences that Asp
and Suc could be potential ciprofloxacin adjuvants to eradicate P. aeruginosa living
within polymicrobial communities. Asp–Cip and Suc–Cip could be promising therapeutic
options to cope with CF treatment failures.
Keywords: Pseudomonas aeruginosa, cystic fibrosis, biofilms, adjuvants, ciprofloxacin, aspartic acid, succinic
acid
INTRODUCTION
Cystic fibrosis (CF) patients suffer from accumulation of thick
and viscous sputum in the airway tract that predisposes them to
the development of airway chronic infections (Ciofu et al., 2014).
A complex community of microbes encompassing bacteria,
fungi, and even viruses can colonize the lungs of CF patients
and establish chronic infections responsible for the increased
mortality rate of these patients (Dickson et al., 2013; Magalhães
et al., 2016a). Within the CF microbiome, Pseudomonas
aeruginosa is considered the most relevant pathogenic agent
responsible for the development of chronic infections, decreased
quality of life, long hospitalizations, and ultimately the number
of deaths (Bittar et al., 2008; Bhagirath et al., 2016). Once P.
aeruginosa enters in the CF lungs, it is hard to be eradicated, even
using aggressive and long antibiotic treatments. The remarkable
switch of P. aeruginosa between an acute and CF-adapted chronic
phenotype exhibiting antibiotic resistance, biofilm formation
ability, overproduction of alginate (mucoid phenotype), slow
growth rate (small colony variants, SCV), and loss of motility
seems to be the key for its persistence in CF lungs (Sousa and
Pereira, 2014; Sousa et al., 2018). Moreover, it is becoming
increasingly clear that interspecies interactions can influence
the pathogenesis of P. aeruginosa, also contributing for its
persistence and worsening of the patient’s condition (Magalhães
et al., 2016b; O’Brien and Fothergill, 2017). For instance, CF
patients coinfected with P. aeruginosa and Staphylococcus aureus
have more severe effects on lung function and poorer clinical
prognosis than the patients with mono-infections (Hubert et al.,
2013). The cohabitation with S. aureus hampers the host immune
response against P. aeruginosa and increases P. aeruginosa
virulence and tolerance to antibiotics (Beaudoin et al., 2017;
Hotterbeekx et al., 2017; Limoli et al., 2017). Not so much
frequent but still concerning is the co-isolation of P. aeruginosa
with Burkholderia cenocepacia that is typically associated with
severe infections because of the increase biofilm formation and
host inflammatory response (Coutinho et al., 2011; Bragonzi
et al., 2012).
Numerous antimicrobial strategies have been used varying in
the route of antibiotic administration (systemic, oral, inhaled
antibiotics, or route combination), classes of antibiotics and
treatment duration in attempt to eradicate P. aeruginosa chronic
infections (Waters and Smyth, 2015; Emiralioglu et al., 2016).
However, these therapies are often unsuccessful, mostly due
to biofilms that are microbial communities encased in a
self-produced matrix that provide to the resident organisms
augmented tolerance to antibiotics (Lopez et al., 2010). Their
impressive high level of antimicrobial tolerance results from
the combination of several mechanisms, including restricted
penetration of antibiotics through the matrix, slow growth
of bacteria within biofilms due to nutritional constraints and
restricted oxygen penetration, quorum-sensing, expression of
biofilm-specific genes, and the presence of persister cells (Mah,
2012; Jorge et al., 2019).
The lack of new antibiotics on the horizon forces the
community to seek alternative therapeutic strategies in order
to restore the action of the in-use antibiotics. A promising
approach is the use of “helper compounds” or adjuvants that
enhance the activity of antibiotics. By definition, antibiotic
adjuvants are compounds with little or no antibiotic activity,
but when combined or coadministered with an antibiotic,
they block the main resistance mechanisms or potentiate the
antibiotic action (Kalan and Wright, 2011; Brown, 2015).
Adjuvant therapies typically include antibiotic combinations,
long used in CF therapeutics (e.g., ciprofloxacin and colistin)
and synergy between antibiotics and non-antibiotics (e.g., ß-
lactamase inhibitors, efflux pump inhibitors, outer-membrane
permeabilizers) (Kalan and Wright, 2011; Döring et al., 2012).
However, antibiotic adjuvants can also include compounds that
alter the physiological state of antibiotic tolerant cells, such
as those in biofilms (Kalan and Wright, 2011). Compounds
that act on the prevention of biofilm formation, disruption
of biofilm integrity, or dispersal to planktonic state (a more
susceptible state) might have great potential to function as
antibiotic adjuvants.
Several natural, synthetic, or biological anti-biofilm
approaches have been investigated including nutrient-induced
dispersals (e.g., succinate, glutamate, glucose, nitrite oxide,
D-amino acids), matrix disruptive enzymes (e.g., DNase I,
Dispersin B, alginate lyase, glutathione), iron chelators (e.g.,
EDTA, lactoferrin), quorum-sensing inhibitors, bacteriophages,
and altered pH (Sauer et al., 2004; Banin et al., 2006; Pires
et al., 2011; Lebeaux et al., 2014a; Brackman and Coenye, 2015;
Chambers et al., 2017; Das et al., 2017; Aliashkevich et al., 2018).
Despite that some of these approaches having demonstrated
some effect against P. aeruginosa biofilms, they were not tested
on biofilms formed in conditions that mimic the CF airway
environment. Airway CF biofilms are genetic, proteomic, and
physiologically different from the surface-attached biofilms
that most of the studies use in their investigations. Instead
of the direct surface colonization, bacteria in the CF lungs
preferentially form aggregates and biofilms within the sputum
and not on the surface epithelium in the bronchi and non-
respiratory bronchioles (Singh et al., 2000; Worlitzsch et al.,
2002; Bjarnsholt et al., 2009). Therefore, the main goal of
this study was to find compounds that can act as antibiotic
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adjuvants augmenting ciprofloxacin action against polymicrobial
biofilms containing P. aeruginosa formed in an in vitro CF
airway environment. To mimic the airway CF biofilms, we used
a previously established artificial sputum medium (ASM) to
closely simulate the physicochemical conditions of CF lungs
and promote the formation of free-floating biofilms within
ASM as demonstrated by Sriramulu et al. (2005). The dual
therapies of compounds and ciprofloxacin were applied before
bacterial growth in ASM, prophylaxis approach, to prevent or
minimize bacterial growth and biofilm formation, and after
24 h of bacterial growth, the treatment approach, to dismantle
biofilms and eradicate planktonic and sessile cells. In this
study, we selected ciprofloxacin because it is one of the most
prescribed antibiotics to treat P. aeruginosa infections, including
those developed in CF lungs (Döring et al., 2012; Remmington
et al., 2016). The compounds selected to act as adjuvants were
previously described as broad-spectrum biofilm-controlling
agents that did not target essential biological functions, but they
had an extensive action on biofilms. They included (i) succinic
acid as a carbon source that promoted biofilm-cell dispersion to
planktonic state (Sommerfeld Ross and Fiegel, 2012); (ii) aspartic
acid and glutathione as disrupting agents of biofilm integrity
(Klare et al., 2016; Bahamondez-Canas and Smyth, 2018); (iii)
galactose as anti-adhesion agent inhibiting biofilm formation
(Hauber et al., 2008); and (iv) acylases I as quorum sensing
inhibitor (Xu et al., 2003).
MATERIALS AND METHODS
Bacterial Strains and Culture Conditions
P. aeruginosa PAO1 and a clinical isolated PAI were used
throughout this study. The rationale behind the selection of these
strains was based on their distinct susceptibility to ciprofloxacin
determined in this study. PAO1 is a laboratory and low-virulence
strain, and PAI is a respiratory clinical isolate kindly provided
by the Hospital of Braga (Braga, Portugal) (Pires et al., 2011).
One CF clinical isolate of S. aureus and B. cenocepacia was used
to evaluate the influence of the most relevant non-pseudomonal
species resident in CF lungs on the efficacy of the dual therapies.
Bacteria were routinely cultured on Tryptic Soy Broth (TSB,
Liofilchem) or Tryptic Soy Agar (TSA, Liofilchem) at 37◦C. All
strains were preserved in criovials (Nalgene) at −80 ± 2◦C to
minimize putative adaptation to the laboratory environment.
Prior to each experiment, bacterial cells were grown on TSA
plates overnight at 37◦C.
Determination of Minimum Inhibitory
Concentration (MIC)
The antibiotic susceptibility of P. aeruginosa strains was
determined by MIC using the microdilution assay following
the recommendations of the Clinical and Laboratory Standards
Institute (CLSI, formerly the National Committee for Clinical
Laboratory Standards) (CLSI 2007). Overnight cultures of P.
aeruginosa strains were washed and diluted with Mueller
Hinton Broth (MHB) to 5 × 105 CFU/mL and transferred
to 96-well plates. Further, bacterial strains were exposed to
different concentrations of ciprofloxacin (Fluka) ranging from
0.03 to 16 mg/L at 37◦C, 120 rpm, for 18–21 h in air
conditions. MIC was determined by the minimum concentration
of antibiotic required to inhibit 90% of growth, measuring
the optical density at 620 nm on a microtiter plate reader
(EZ Read 800 Plus, Biochrom). The clinical breakpoint for
ciprofloxacin was 4 mg/L as defined by CLSI (CLSI 2007). MHB
alone and bacterial cultures free of ciprofloxacin were used
as negative and positive controls, respectively. All tests were
performed five times (independent biological assays) with three
technical replicates.
In vitro Growth of P. aeruginosa in an in
vitro CF Airway Environment
Artificial Sputum Medium Preparation
Artificial sputum medium (ASM) was used to mimic the sputum
of CF patients, and it was prepared as described by Sriramulu
et al. (2005). Briefly, 5 g/L of mucin from pig stomach (Sigma-
Aldrich), 4 g/L of DNA from salmon sperm (Sigma-Aldrich),
5.9 mg/L of diethylenetriaminepentaacetic acid (DTPA, Sigma-
Aldrich), 5 g/L of NaCl, 2.2 g/L of KCl, and 5 g/L of casoamino
acids (AMESRO) were resuspended in water and the pH adjusted
to 7 with Tris base. This ASM was then sterilized in an autoclave
at 110◦C for 15min, and after being cooled, 5mL of egg yolk
emulsion (Fluka) was added.
Preparation of Stock Solutions of the Compounds
Distilled sterile water was used for water-soluble molecules,
including glutathione (Sigma-Aldrich), galactose (Sigma-
Aldrich), and succinic acid (VWR Chemicals). Galactose,
L-aspartic acid, and acylases I were dissolved in 0.9M NaCl,
2M NaOH, and 100mM potassium phosphate buffer, pH 7,
respectively, according to the manufacturer’s recommendations
(Sigma-Aldrich). Concentrated solutions of the compounds
were prepared and applied to ASM cultures to obtain a final
concentration of 20mM of aspartic acid, succinic acid, and
galactose, 10mM of glutathione, and 5 and 15 mg/L of acylases
I as described in literature (Xu et al., 2003; Sauer et al., 2004;
Klare et al., 2016; Bahamondez-Canas and Smyth, 2018). All
stock solutions were freshly prepared before their application
on ASM. Three different concentrations of ciprofloxacin, two
subinhibitory concentrations and one inhibitory concentration
according to the MIC values obtained for the P. aeruginosa
strains, were combined with the compounds.
Anti-pseudomonal Activity of Ciprofloxacin
Combined With Compounds
Dual therapies were applied as prophylaxis, before P. aeruginosa
growth in ASM, and as treatment, after 24 h of bacterial growth
in ASM and the formation of biofilms, as demonstrated by
Sriramulu et al. (2005). In the prophylactic application, dual
therapies were first applied to ASM followed by P. aeruginosa.
Overnight inocula of each P. aeruginosa strain were washed
twice in sterile water by centrifugation (9,000 g, 5min) and
further serial diluted in sterile water. Two milliliters of ASM
was transferred to each well of a 24 well-plate (polystyrene,
Orange, USA), and the dual therapies were added. After 30min,
ASM was inoculated on the top with 5 µL of the bacterial cell
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suspensions, obtaining a final cellular concentration in each well
of 1 × 107 CFU/mL. ASM cultures were incubated for 24 h
at 37◦C aerobically in static culture conditions to resemble the
reduced or absent cilia movements in CF lungs (Worlitzsch et al.,
2002; Hassett et al., 2009). The content of the wells was then
collected aseptically and vigorously shaken to detach cells from
possible small aggregates or cells adhered to the mucin. The
resulting cell suspensions, corresponding to the whole resident
populations in ASM, were plated on TSA to determine the
number of culturable cells that survived after the prophylactic
application of the dual therapies. In the treatment approach,
P. aeruginosa was first added to ASM as aforementioned and
allowed to grow for 24 h to form biofilms as demonstrated by
Sriramulu et al. (2005). After, the dual therapies were added
to ASM, containing the 24-h-old planktonic cells and biofilms,
and their efficacy evaluated after 24 h by counting the culturable
cells that survived. All experiments were performed at least
five times.
Antimicrobial Effect of the Dual Therapies on
Polymicrobial Communities
The prophylactic effectiveness of the dual therapies for
eradication of the polymicrobial communities of bacteria from
ASM was determined as described above with few modifications.
First, ASM was inoculated with bacterial cell suspensions of
S. aureus and P. aeruginosa or with B. cenocepacia and P.
aeruginosa, obtaining a final concentration of 1 × 107 CFU/mL
for each bacterial species. ASM cultures were incubated at
37◦C for 24 h aerobically and in static culture conditions, and
the number of culturable cells that survived determined. To
investigate the effectiveness of the treatment approach, ASM
was first inoculated with bacterial cell suspensions of S. aureus
and P. aeruginosa or with B. cenocepacia and P. aeruginosa at
a final concentration of 1 × 107 CFU/mL for each species and
cultures incubated at 37◦C for 24 h aerobically and in static
culture conditions to allow mixed biofilm formation. After, the
ASM containing mixed planktonic cells and 24-h-old biofilms
was exposed to the dual therapies for 24 h. The whole content
of ASM, corresponding to the whole resident populations, was
then plated on selective solid media to discriminate each species.
P. aeruginosa was plated on Pseudomonas isolation agar (Sigma-
Aldrich) or cetrimide (Liofilchem) if it grew with S. aureus or B.
cenocepacia, respectively. S. aureus was plated on Mannitol salt
agar (Liofilchem) and B. cenocepacia was plated on Burkholderia
selective agar (Oxoid) with 150 000 IU/L of polymyxin B, 5 mg/L
of gentamicin, and 100 mg/L of ticarcillin.
Cytotoxicity of the Dual Therapies on Lung Epithelial
Cells
Cytotoxicity of the most promising dual therapies was evaluated
on human lung epithelial A549 cells (ATCCCCL-185). Cells were
grown in Dulbecco modified eagle medium (DMEM, Gibco)
supplemented with 10% of fetal bovine serum (FBS, Gibco)
and 1% antibiotics (ZellShieldTM, Biochrom) at 37◦C, 5% CO2.
Once having achieved a minimum of 80% confluence, cells were
detached, using trypsin, and adjusted to a final concentration of 1
× 105 cells/mL. Then, 100 µL of cell suspension was transferred
to each well of a 96-well plate, which was incubated for 24 h at
37◦C, 5% CO2. After this period, cell culture supernatant was
removed and 100 µL of dual therapies prepared in supplemented
DMEM was added. Fresh culture media with no compounds
were also added as a positive control. The plate was incubated for
an additional 24 h at 37◦C, 5% CO2. Metabolic activity of cells
was determined using the MTS [(3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)]
inner salt (Promega) assay. Briefly, in the dark, 20 µL of
MTS was added to each well and the plate was further
incubated for 1 h at 37◦C, 5% CO2. The optical density of
the resulting solution was measured at 490 nm. Results were
presented as percentage of viable cells compared to the positive
control. Two independent experiments, using four replicates,
were performed.
Statistical Analysis
All graphs and statistical data analysis were performed using
GraphPad Prism software package (GraphPad Software version
8.2.0). Means and standard deviation were calculated for all
experimental conditions tested. Statistical analysis was carried
out by ANOVA with Tukey’s multiple comparison, and p-values
< 0.05 were considered significant.
RESULTS
To assess the adjuvant potential of the selected compounds, a
P. aeruginosa strain susceptible (MIC of 0.125–0.5 mg/L) and
another resistant to ciprofloxacin (MIC of 4 mg/L), PAO1 and
PAI, respectively, were used on the combination studies with
ciprofloxacin. The control studies of the antimicrobial activity
of the compounds, when acting alone, stated that they had
no antimicrobial effect with exception of aspartic acid and
succinic acid (Figures 1, 2). These two compounds demonstrated
some inhibitory action against the two P. aeruginosa strains
grown in ASM. Moreover, the control studies for the action
of ciprofloxacin alone were performed and the subinhibitory
and inhibitory concentrations of ciprofloxacin were unable to
eradicate P. aeruginosa grown in ASM using either a prophylactic
or a treatment approach (Figures 1, 2).
Prophylactic Application of the Dual
Therapies
Results obtained for the synergistic activity of compounds and
ciprofloxacin showed that, overall, prophylactic application of
dual therapies showed better activity against P. aeruginosa than
the treatment approach (Figures 1, 2). All the compounds
tested enhanced the activity of, at least, one concentration of
ciprofloxacin, achieving a significant bacterial load reduction
of the whole P. aeruginosa population resident in ASM (p <
0.05). However, not all the compounds aided the ciprofloxacin
action against both P. aeruginosa strains or even aided in
bacterial eradication. Only aspartic acid and succinic acid
demonstrated adjuvant potential against both P. aeruginosa
strains, as evidenced by the lower number or absence of
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FIGURE 1 | Inhibition of (A) P. aeruginosa PAO1 and (B) PAI growth by subinhibitory (1 and 2 mg/L) and inhibitory (4 mg/L) concentrations of ciprofloxacin alone and
combined with 20mM of galactose, aspartic acid, and succinic acid, 10mM of glutathione, and 5 and 15 mg/L of acylases I. Values represent mean ± standard
deviation of, at least, 5 independent experiments. The differences in log10 CFU/mL of the growth of P. aeruginosa strains after the application of the dual therapies
were compared to ciprofloxacin when acting alone, and the differences in log10 CFU/mL of the growth of P. aeruginosa strains after the application of the compounds
alone were compared to untreated populations using two-way ANOVA followed by Tukey’s multiple comparison post hoc test. Significant differences are indicated by
asterisks: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. CFU, colony-forming units; CIP, ciprofloxacin; GAL, galactose; GSH, glutathione; ACY, acylases I; ASP,
aspartic acid; SUC, succinic acid.
culturable cells compared to the ciprofloxacin when acting alone
(Figure 1).
The improvement introduced by the aspartic acid to
ciprofloxacin action was clearly evident for all concentrations
tested and against both P. aeruginosa strains. The combination
of aspartic acid with the lowest subinhibitory concentration
of ciprofloxacin (1 mg/L) resulted in a significant bacterial
load reduction of around 5 log for PAO1, compared with
ciprofloxacin alone. This result was further improved, increasing
the subinhibitory concentration of ciprofloxacin 2-fold (2 mg/L),
as evidenced by the eradication of PAO1 from ASM. PAO1
eradication was also obtained combining aspartic acid with the
inhibitory concentration of ciprofloxacin (4 mg/L). The dual
therapy of the aspartic acid with ciprofloxacin (Asp–Cip) was
more efficient against PAO1 than against the resistant strain,
PAI. However, the significant load reduction of this resistant
strain, ranging from 4 to 5 log, in comparison with ciprofloxacin
alone must be emphasized. This reduction is notorious from a
microbiological point of view.
The greatest improvements to ciprofloxacin action were
introduced by succinic acid because its combination with
the subinhibitory concentration of 2 mg/L of ciprofloxacin
eradicated PAO1 and PAI from ASM. An identical result
was obtained combining succinic acid with the inhibitory
concentration of ciprofloxacin (4 mg/L).
Application of the Dual Therapies as
Treatment
As expected, the application of the dual therapies as treatment,
meaning their application after 24 h of bacterial growth
and biofilm formation in ASM was not as efficient as
the prophylactic application. Among all the dual therapies
tested, Asp–Cip was the only combination that presented
anti-pseudomonal activity (Figure 2). Combined with aspartic
acid, 2 mg/L of ciprofloxacin provoked a 3-log reduction of
the whole PAO1 population, and 4 mg/L of ciprofloxacin
seemed to eradicate the 24-h-old PAO1 planktonic and
biofilm cells, in comparison with ciprofloxacin when acting
alone. Aspartic acid also improved ciprofloxacin action against
24-h-old PAI populations in a similar way for the three
concentrations tested, obtaining a reduction of 4 log. However,
when aspartic acid acted alone, it produced identical log
reduction, which led us to consider that the dual-therapy
effect was caused by the action of aspartic acid and not by
the combination.
The Most Promising Dual Therapies and
Their Long-Term Effect
Based on the results obtained so far, aspartic acid and succinic
acid were understandably selected as the most promising
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FIGURE 2 | Killing activity of 24-h-old populations of (A) P. aeruginosa PAO1 and (B) PAI by subinhibitory (1 and 2 mg/L) and inhibitory (4 mg/L) concentrations of
ciprofloxacin alone and combined with 20mM of galactose, aspartic acid and succinic acid, 10mM of glutathione, and 5 and 15 mg/L of acylases I against. Values
represent mean ± standard deviation of, at least, 5 independent experiments. The differences in log10 CFU/mL of P. aeruginosa strains after the application of the dual
therapies were compared to ciprofloxacin when acting alone, and the differences in log10 CFU/mL of P. aeruginosa strains after the application of the compounds
alone were compared to untreated populations using two-way ANOVA followed by Tukey’s multiple comparison post hoc test. Significant differences are indicated by
asterisks: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. CFU, colony-forming units; CIP, ciprofloxacin; GAL, galactose; GSH, glutathione; ACY, acylases I; ASP,
aspartic acid; SUC, succinic acid.
adjuvants of ciprofloxacin. To select the most promising
combination therapies using these compounds, two criteria were
used: to provoke bacterial eradication or, at least, reduce 3
log the bacterial load present in ASM; and to have effect on
the two P. aeruginosa strains. Based on these criteria, the Suc-
and Asp-2 mg/L Cip therapies were selected for prophylactic
approach and Asp-4 mg/L Cip for treatment application. Suc-
2 mg/L Cip therapy eradicated both P. aeruginosa strains,
but also Asp-2 mg/L Cip exhibited interesting results for
prophylaxis since it eradicated PAO1 and significantly reduced
PAI bacterial load. Asp-4 mg/L Cip was the only combination
therapy applied as treatment able to eradicate the whole PAO1
population, including planktonic cells and biofilms, and reduce
PAI population with microbiological significance.
Despite the promising results obtained so far, it was of
utmost importance to ensure that a relapse of infection did
not occur after ending the effect of the dual therapies. Relapse
of infection can occur through the recovery of the population
that was not completely eradicated or through the presence of
dormant cells, including viable but non-culturable cells (VBNC)
and persister cells (not detected in solid media). Therefore, this
study aimed at investigating the behavior of the P. aeruginosa
populations after the effect of the combination therapies had
ended. The detection of VBNC and persister cells is typically
performed using advanced methods, e.g., flow cytometer, but
growing bacteria in ASM implies the optimization of the ASM
preparation, which is not concluded in our laboratory yet.
Nevertheless, a simple way to gain insights about the presence
of these two kinds of dormancy states within P. aeruginosa
populations is a long-term monitoring of the bacterial growth
for several days after the application of the dual therapies
(Fisher et al., 2017; Ayrapetyan et al., 2018). The results revealed
that dormant cells might not yet be present in P. aeruginosa
populations as no culturable cells were detected on the solid
medium along 6 days after application of Asp-2 mg/L Cip
against PAO1 (Figure 3A) and after the application of Suc-
2 mg/L Cip against PAO1 and PAI (Figure 4). However, we
observed that PAI load reduction provoked by Asp-2 mg/L Cip
was only kept for 24 h and a full recovery of population was
attained after 3 days (Figure 3B). This finding led us to consider
Suc-2 mg/L Cip as the most suitable therapy to be applied
as prophylaxis.
Our results also indicated that the 24-h-old PAO1 population
that encompassed biofilms might not include VBNC or
persister cells since no culturable cells were detected after
ending the Asp-4 mg/L Cip effect, in contrast with PAI
populations that recovered their initial bacterial load (data
not shown).
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FIGURE 3 | Long-term effect of the prophylactic application of 2 mg/L ciprofloxacin alone and combined with aspartic acid on (A) P. aeruginosa PAO1 and (B) PAI
during 6 days. Values represent mean ± standard deviation of, at least, three independent experiments. The differences in log10 CFU/mL of P. aeruginosa strains after
the application of Asp–Cip were compared to ciprofloxacin when acting alone (indicated by asterisks), and the differences in log10 CFU/mL of P. aeruginosa strains
after the application of the aspartic acid alone were compared to untreated populations (indicated by hashtag), using two-way ANOVA followed by Tukey’s multiple
comparison post hoc test. Significant differences are indicated as follows: ***/###p < 0.001, ****/####p < 0.0001. CFU, colony-forming units; CIP, ciprofloxacin;
ASP, aspartic acid.
FIGURE 4 | Long-term effect of the application of 2 mg/L ciprofloxacin alone and combined with succinic acid as treatment on 24-h-old populations of (A)
P. aeruginosa PAO1 and (B) PAI during 6 days. Values represent mean ± standard deviation of, at least, three independent experiments. The differences in log10
CFU/mL of P. aeruginosa strains after the application of Suc–Cip were compared to ciprofloxacin when acting alone (indicated by asterisks), and the differences in
log10 CFU/mL of P. aeruginosa strains after the application of succinic acid alone were compared to untreated populations (indicated by hashtag), using two-way
ANOVA followed by Tukey’s multiple comparison post hoc test. Significant differences are indicated as ****/####p < 0.0001. CFU, colony-forming units; CIP,
ciprofloxacin; SUC, succinic acid.
Effect of Asp-Cip and Suc-Cip Therapies
on Polymicrobial Communities
We investigated the outcome of the most effective dual therapies
on P. aeruginosa when it lives in polymicrobial communities.
The adjuvant effect of succinic acid on ciprofloxacin against P.
aeruginosa was preserved in the presence of S. aureus and B.
cenocepacia, when this dual therapy was applied prophylactically
(Figures 5A,B). PAO1 and PAI seemed to be identically
eradicated from ASM compared to the monocultures (Figure 1).
Nevertheless, we must pay much attention to the effect of the
dual therapies on off-target species including S. aureus and
B. cenocepacia that share a CF airway environment with P.
aeruginosa. Suc–Cip therapy showed a positive “collateral” effect
because eradicated B. cenocepacia along with P. aeruginosa.
Succinic acid seemed to improve the ciprofloxacin action since
this antibiotic alone was not able to eradicate this bacterial
species. The interspecies interaction established between B.
cenocepacia and P. aeruginosamight play a role in B. cenocepacia
eradication because the dual therapy did not eliminate B.
cenocepacia grown alone (Figure 5C).
In contrast to B. cenocepacia, the Suc–Cip therapy did not
have activity on S. aureus growing with or without P. aeruginosa.
Nevertheless, we noted that succinic acid alone had a distinct
effect on P. aeruginosa and S. aureus compared to monocultures.
This compound seemed to induce cell death of both bacterial
species, whose eradication was not achieved by the Suc–Cip
therapy (Figures 5A,B). In this case, ciprofloxacin seemed to
compromise the action of succinic acid in the eradication of this
mixed community.
The anti-pseudomonal effect of Asp–Cip was not affected by
the presence of S. aureus and B. cenocepacia (Figures 6A,B).
PAO1 and PAI were identically eradicated and reduced,
respectively, within 24-h-old mixed populations in comparison
with the pseudomonal monocultures (Figure 2). Similar to Suc–
Cip, Asp–Cip therapy demonstrated to be an interesting therapy
against B. cenocepacia as this species was eradicated from
ASM, demonstrating that aspartic acid has also functioned as
adjuvant of ciprofloxacin in B. cenocepacia eradication. Again,
interaction with P. aeruginosa seemed somehow to sensitize B.
cenocepacia to eradication by Asp–Cip because monocultures
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FIGURE 5 | Inhibitory effect of 2 mg/L of ciprofloxacin alone and combined with succinic acid against (A) P. aeruginosa PAO1 and (B) PAI with S. aureus and B.
cenocepacia and (C) against monocultures of S. aureus and B. cenocepacia. Values represent mean ± standard deviation of two independent experiments. The
differences in log10 CFU/mL of the bacterial strains after the application of the dual therapies were compared to ciprofloxacin when acting alone, and the differences in
log10 CFU/mL of the bacterial strains after the application of the compounds alone were compared to untreated populations using two-way ANOVA followed by
Tukey’s multiple comparison post hoc test. Significant differences are indicated by asterisks: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. CFU,
colony-forming units; CIP, ciprofloxacin; SUC, succinic acid.
of B. cenocepacia were not sensitive to the combination
therapy (Figure 6C).
The effect of Asp–Cip on S. aureus within mixed 24-h-old
populations was variable. When S. aureus shared ASM with
PAO1, a sensitive strain to ciprofloxacin, Asp–Cip eradicated S.
aureus along with P. aeruginosa, but when it shared with PAI,
a ciprofloxacin-resistant strain, S. aureus survived this therapy
together with PAI.
Effect of the Most Promising Dual
Therapies on the Metabolic Activity of
Lung Epithelial Cells
In addition to the anti-pseudomonal effect of the dual therapies
tested, it was important to understand their effect on the
human cells. Therefore, a cytotoxic assay was performed using
lung epithelial cells. Ciprofloxacin and aspartic acid, alone or
combined, proved to be non-toxic, as evidenced by the cell
viability higher than 70% (Figure 7). Addition of succinic acid
to ciprofloxacin, on the other hand, impaired the growth of
these cells as demonstrated by the absence of metabolic activity.
The acidic nature provided by the presence of succinic acid
(Table S1), when added to the culture media, may be the
reason for these results since succinic acid alone obtained
identical cytotoxicity.
DISCUSSION
The strategies used by bacteria to resist to antibiotics are not
always dependent on intrinsic features or acquiring genetic
elements, but instead, resistance can be expressed through an
alteration in bacterial lifestyle (Lebeaux et al., 2014b). The
biofilm lifestyle is considered one of the most important adaptive
mechanisms of P. aeruginosa within CF sputum (Høiby et al.,
2010). The hallmark of biofilms is their impressive multifactorial
way to resist to antibiotics that conventional treatments rarely
have effect (Borriello et al., 2004; Rose and Poppens, 2009; Soares
et al., 2019). Compounds that interfere with biofilm lifecycle,
e.g., inhibition of the adhesion, or interfere with biofilm lifestyle,
e.g., induce dispersion and disruption of matrix, are highly
convenient, but most of the biofilm-controlling compounds
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FIGURE 6 | Killing effect of 4 mg/L of ciprofloxacin alone and combined with aspartic acid against mixed 24-h-old populations of (A) P. aeruginosa PAO1 and (B) PAI
with S. aureus and B. cenocepacia and (C) against monocultures of S. aureus and B. cenocepacia. Values represent mean ± standard deviation of two independent
experiments. The differences in log10 CFU/mL of the bacterial strains after the application of the dual therapies were compared to ciprofloxacin when acting alone, and
the differences in log10 CFU/mL of the bacterial strains after the application of the compounds alone were compared to untreated populations using two-way ANOVA
followed by Tukey’s multiple comparison post hoc test. Significant differences are indicated as follows: ***p < 0.001, #p < 0.0001. CFU, colony-forming units; CIP,
ciprofloxacin; ASP, aspartic acid.
do not kill the biofilm cells and, thus, the combination with
antibiotics can be a promising strategy. Moreover, biofilm
disassembly either by disruption or by dispersal is associated with
a massive release of bacteria, which can represent a serious risk to
patients if it would be not combined with the use of antibiotics;
for instance, bacteria can enter into the bloodstream leading to
sepsis (O’Toole, 2004).
Several effective anti-biofilm strategies were proposed, but
until now they have not passed through clinical trials and
entered the commercial market (Romero and Kolter, 2011;
Lu et al., 2019). The lack of anti-biofilm agents available for
the treatment of CF patients led us to rethink the choice
of the biofilm-controlling compounds to be tested. Typically,
researchers look for novel antibiotic adjuvants species-specific
with a specific mode of action, for instance the inhibition of
resistance enzymes, efflux pumps, or quorum sensing. This
approach implies a great domain of species intrinsic and
adaptive resistance mechanisms, including biofilm physiology
and structure and the gene expression profile while forming
and living in biofilms. In this study, we opted mostly for
potential broad-spectrum compounds that had an extensive
effect on biofilms. This kind of approach is being followed
by some authors, for instance, Reffuveille et al. (2014) which
reported that the synthetic peptide 1018 had broad-spectrum
activity as adjuvant for different antibiotic against biofilms
formed by multidrug-resistant bacteria. However, compounds
such as peptide 1018 will certainly find constrains in its
therapeutic approval because it is a new drug. To overcome
the prolonged development timelines of therapy approval, we
mainly selected FDA-approved compounds or nutrients to
facilitate, in the future, the advance of the therapies for the next
clinical stages.
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FIGURE 7 | Cytotoxicity of 2 and 4 mg/L of ciprofloxacin alone and combined with succinic acid and aspartic acid, respectively. Lung epithelial cell viability was
measured using MTS assay. Values represent mean ± standard deviation of two independent experiments. The viability percentage shown is compared to untreated
samples. The differences in cell viability percentage compared to ciprofloxacin when acting alone were determined using one-way ANOVA followed by Tukey’s multiple
comparison post hoc test. Significant differences are indicated by asterisks: ***p < 0.001, ****p < 0.0001. CIP, ciprofloxacin; ASP, aspartic acid; SUC, succinic acid.
Fluoroquinoles, in particular ciprofloxacin, is an important
component of anti-pseudomonal chemotherapy in the treatment
of the polymicrobial CF-associated infections (Langan et al.,
2015; Emiralioglu et al., 2016), and, for this reason, it was the
antibiotic chosen to search for adjuvants.Moreover, ciprofloxacin
is among the priority antibiotics for which adjuvants are
demanded (Brown, 2015) and our results clearly stated this
need because subinhibitory and inhibitory concentrations of
ciprofloxacin were unable to eradicate P. aeruginosa grown
in ASM. It should be noted that in our study the inhibitory
concentration of ciprofloxacin did not inhibit the growth
of the susceptible strain. This result evidenced the difficulty
that the CF airway environment poses to drug development.
The presence of thick and viscous sputum in the CF lungs
provides a narrow mesh that slows down or even impairs the
efficient penetration of the antimicrobial molecules, resulting
in the therapy failure and bacterial survival (Suk et al.,
2009).
We found that aspartic acid and succinic acid revitalized
ciprofloxacin action against P. aeruginosa. To the best of
our knowledge, aspartic acid and succinic acid are not used
as antimicrobial agents, for adjuvant therapy, or for other
therapeutic purposes, but they are only taken as nutritional
supplements (information retrieved from DrugBank database).
Nonetheless, some studies have used them as biofilm-controlling
compounds (Sauer et al., 2004; Parks et al., 2009; Yang et al.,
2015; Bahamondez-Canas and Smyth, 2018). According to
the literature findings, aspartic acid acts as an anti-adhesion
and disrupting agent of biofilms formed in the CF airway
environment. Parks et al. (2009) demonstrated that aspartic
acid had the capacity to dissolve DNA and F-actin (released
from necrotic neutrophils) bundles associated with histones.
This dissociation dismantles early biofilm structures or impair
biofilm formation. Even though we did not measure biofilm
formation and disassembly, due to technical difficulties imposed
by the ASM characteristics to separate free-floating biofilm
from planktonic cells, we hypothesized that aspartic acid
similarly inhibited or impaired biofilm formation, when applied
prophylactically, and dismantled biofilms, when applied as
treatment, as described by Parks et al. (2009). However, other
mechanisms of action not related to biofilm growth should
be considered. This compound when acting alone induced
planktonic cell death, reducing significantly the bacterial load
present in ASM, which could also contribute to the bacterial
reduction or eradication of ciprofloxacin when acted along with
aspartic acid.
Several studies have demonstrated that succinic acid reduces
P. aeruginosa biofilm survival acting mainly as a dispersion
agent (Sommerfeld Ross and Fiegel, 2012; Bahamondez-
Canas and Smyth, 2018). However, our results of the whole
biomass depletion after the application of Suc–Cip therapy
showed that the adjuvant effect of succinic acid was more
pronounced before bacterial growth and biofilm formation
than against the 24-h-old P. aeruginosa populations that
included biofilms, as demonstrated by Sriramulu et al. (2005).
This finding could lead us to consider succinic acid for
anti-biofilm (or aggregate) formation, but it would not
explain the ability of ciprofloxacin to eliminate resistant
bacteria. Even if ciprofloxacin-resistant bacteria, in our study
represented by PAI, were unable to form biofilms or small
aggregates and remained in planktonic state, resistance is
still expressed, and ciprofloxacin action would be comprised.
However, Suc–Cip therapy eliminated planktonic resistant
bacteria, and thus we hypothesized that succinic acid somehow
blocked or reduced the expression of ciprofloxacin resistance.
As far as we know, this is the first report showing a
different helping role of succinic acid. This synergistic action
between succinic acid and ciprofloxacin must be urgently
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addressed because it could represent a significant advance in
CF therapeutics.
A fundamental feature when an innovative therapy is under
development is the ability to avoid or, at least, minimize the
chances of a relapse. Our data emphasized that eradication
of bacteria must be efficiently performed, otherwise bacteria
can recover giving rise to a relapse of infection. Although
Asp–Cip and Suc–Cip therapies have eradicated bacteria from
ASM, relapse of infection can still occur due to the existence
of VBNC or persister cells within P. aeruginosa populations.
VBNC are a subpopulation of bacteria that become non-
culturable on media but functionally viable and able to return
to a metabolically active and culturable state (Oliver, 2010; Li
et al., 2014). In turn, persister cells represent about 1% of
the population that survive to antibiotic treatments despite not
being antibiotic resistant (Conlon et al., 2015; Fisher et al.,
2017). Both VBNC and persister cells can be induced by
stressful conditions, such as an antibiotic treatment (Kubistova
et al., 2017; Ayrapetyan et al., 2018) and biofilms (Pasquaroli
et al., 2013; Ayrapetyan et al., 2018; Soares et al., 2019). The
detection of dormant cells should be preferentially performed
using advanced techniques, such as flow cytometry (Ruger et al.,
2014), but the high viscosity of ASM and its components
(e.g., eDNA, mucin, salts) demands an extensive optimization
of the ASM preparation (before flow cytometry analysis) that
we have not yet concluded in our laboratory. Therefore, we
performed a long-term monitoring of bacterial regrowth as
previously described (Fisher et al., 2017; Ayrapetyan et al., 2018)
to gain insights about the presence of VBNC and persister
cells within P. aeruginosa populations. The eradication effect
of Asp–Cip and Suc–Cip was lasting, indicating the absence
of VBNC and/or persisters within P. aeruginosa populations
including within biofilms. Nevertheless, additional analyses
should be performed to ensure the absence of VBNC and
persister cells.
Asp–Cip and Suc–Cip therapies accomplished two important
features of an antimicrobial CF therapy. Firstly, they exhibited
anti-pseudomonal activity, and secondly, this activity had a long-
term effect without bacterial regrowth. However, P. aeruginosa
does not live alone in CF lungs. CF airway environment is a
“rich soup” of microorganisms where interspecies interactions
including interdependencies, competition, antagonism, and
synergism among the resident members can define the survival
of the P. aeruginosa and the infection course (Harrison, 2007;
Tavernier et al., 2017). The interspecies interaction between
P. aeruginosa and S. aureus is the most studied relationship
in the CF context. S. aureus is the main responsible for the
bacterial infections in younger CF patients, and it is typically
a “precursor” of P. aeruginosa in CF lung colonization (Cystic
Fibrosis Foundation, 2017). Several studies have reported that
S. aureus can protect P. aeruginosa from uptake by the host
immune cells and antibiotic action, promoting, for instance,
the selection of SCV (Michelsen et al., 2014; Armbruster et al.,
2016; Beaudoin et al., 2017). Burkholderia sp. predominates in
older CF patients, and the relevance of the B. cenocepacia and
P. aeruginosa interactions arise from some studies that reported
augmented virulence potential on P. aeruginosa, e.g., redox-
active phenazine, peroxides, rhamnolipids, hydrogen cyanide,
and the siderophore pyoverdine (Tomlin et al., 2001; Bakkal
et al., 2010; Bragonzi et al., 2012; Costello et al., 2014;
Tavernier et al., 2017). These phenotypic characteristics are
quite found in CF isolates of P. aeruginosa and fundamental
for the success of infection establishment (Sousa and Pereira,
2014). Despite competing for the same resources, including
oxygen and nutrients, P. aeruginosa and Burkholderia sp.
are able to coexist in biofilms, triggering an increased
inflammatory response (Riedel et al., 2001; Bragonzi et al.,
2012). According to our results, S. aureus and B. cenocepacia
did not affect the anti-pseudomonal activity of Asp–Cip and
Suc–Cip therapies, which reinforced their potential as novel CF
therapeutic option.
Broad-spectrum antibiotic adjuvants can bring about serious
side effects on CF microbiome. It is not desirable that the
eradication of P. aeruginosa from the CF airway environment
provides a window of opportunity for other bacterial species to
thrive. Moreover, at this point, Asp–Cip and Suc–Cip therapies
have had an impressive performance. The eradication of P.
aeruginosa from the polymicrobial communities did not favor
the growth of S. aureus or B. cenocepacia. Indeed, aspartic
acid and succinic acid also act as ciprofloxacin adjuvants
against B. cenocepacia.
In order to appreciate the feasibility of the Asp–Cip and
Suc–Cip therapies for CF application, their cytotoxicity was
evaluated. The choice of nutrients as ciprofloxacin adjuvants
showed some benefits, because Asp–Cip therapy was not toxic to
lung epithelial cells. Although being a nutrient as well, succinic
acid was toxic, which conferred toxicity to Suc–Cip therapy.
This might result from the acidity of succinic acid damaging
the lung epithelial cells. It would be interesting to investigate
if succinic acid preserved its adjuvant potential at lower and
non-cytotoxicity concentrations.
In conclusion, we evidenced that the combination of
an antibiotic with adjuvants with biofilm-controlling features
could be the next wave of antimicrobial CF therapeutics to
combat polymicrobial CF-associated infections. We used ASM
containing the major components of CF sputum, which yielded
P. aeruginosa populations, including planktonic cells and free-
floating biofilms, much more identical to the in vivo airway
CF conditions. We found that succinic acid and aspartic acid,
two nutrients, were promising ciprofloxacin adjuvants in the
inhibition and eradication of bacterial growth and biofilm
formation. Succinic acid and aspartic acid could allow the
lifespan of ciprofloxacin to be extended in CF therapeutics as
well as in other disease contexts. Despite their evident potential,
more studies must be performed in order to tune the adjuvant
concentration and determine the synergisticmechanism of action
underlying these combinations.
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